ATE62902T1 - Triazin-salze. - Google Patents

Triazin-salze.

Info

Publication number
ATE62902T1
ATE62902T1 AT87304776T AT87304776T ATE62902T1 AT E62902 T1 ATE62902 T1 AT E62902T1 AT 87304776 T AT87304776 T AT 87304776T AT 87304776 T AT87304776 T AT 87304776T AT E62902 T1 ATE62902 T1 AT E62902T1
Authority
AT
Austria
Prior art keywords
triazine salts
triazine
salts
dichlorophenyl
diamino
Prior art date
Application number
AT87304776T
Other languages
English (en)
Inventor
David Alan Sawyer
Frederick Charles Copp
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE62902T1 publication Critical patent/ATE62902T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT87304776T 1986-05-30 1987-05-29 Triazin-salze. ATE62902T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868613183A GB8613183D0 (en) 1986-05-30 1986-05-30 Triazine salt
EP87304776A EP0247892B1 (de) 1986-05-30 1987-05-29 Triazin-Salze

Publications (1)

Publication Number Publication Date
ATE62902T1 true ATE62902T1 (de) 1991-05-15

Family

ID=10598692

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87304776T ATE62902T1 (de) 1986-05-30 1987-05-29 Triazin-salze.

Country Status (18)

Country Link
US (1) US4847249A (de)
EP (1) EP0247892B1 (de)
JP (1) JPH0751571B2 (de)
KR (1) KR910002254B1 (de)
AT (1) ATE62902T1 (de)
AU (1) AU597982B2 (de)
CA (1) CA1286670C (de)
DE (1) DE3769516D1 (de)
DK (1) DK166278C (de)
ES (1) ES2021709B3 (de)
FI (1) FI90770C (de)
GB (1) GB8613183D0 (de)
GR (1) GR3001942T3 (de)
HU (1) HU196769B (de)
IE (1) IE60626B1 (de)
IL (1) IL82710A (de)
NZ (1) NZ220497A (de)
ZA (1) ZA873896B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
AU653203B2 (en) * 1991-01-30 1994-09-22 Wellcome Foundation Limited, The Water-dispersible tablets
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
GB9124807D0 (en) * 1991-11-22 1992-01-15 Wellcome Found Pharmaceutical formulations
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
HRP930964B1 (en) * 1992-06-12 2000-06-30 Wellcome Found Therapeutic triazine compounds and the use thereof
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2699078B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application de la lamotrigine dans le traitement de lésions neurologiques liées à des traumatismes.
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5866597A (en) * 1993-03-19 1999-02-02 Glaxo Wellcome Inc. Use of triazine compounds for the treatment of memory and learning disorders
GB9305693D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
GB9306639D0 (en) * 1993-03-30 1993-05-26 Tocris Neuramin Limited Organic compounds
FR2702149B1 (fr) * 1993-06-03 1995-04-07 Rhone Poulenc Rorer Sa Application de la lamotrigine dans le traitement du neuro-sida.
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
DK0800520T3 (da) * 1994-12-30 2002-10-14 Wellcome Found Fremgangsmåde til fremstilling af lamotrigin
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
GB9812413D0 (en) 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
PL348865A1 (en) * 1998-12-14 2002-06-17 Torrent Pharmaceuticals Ltd An improved process for the preparation of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
AU763244B2 (en) * 2000-01-03 2003-07-17 Rpg Life Sciences Limited A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
IL134730A (en) * 2000-02-25 2003-10-31 Chemagis Ltd Process for preparing substituted benzoyl cyanide amidinohydrazones
WO2002068398A1 (en) * 2001-02-27 2002-09-06 Teva Pharmaceutical Industries Ltd. New crystal forms of lamotrigine and processes for their preparations
CA2483103A1 (en) * 2002-04-23 2003-11-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
HU225667B1 (en) * 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es) 2002-10-31 2005-08-01 Vita Cientifica, S.L. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
WO2009061513A1 (en) * 2007-11-09 2009-05-14 Thar Pharmaceuticals Crystalline forms of lamotrigine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR227521A1 (es) * 1979-06-01 1982-11-15 Wellcome Found Procedimiento para la preparacion de derivados de 3,5-diamino-6-(fenil substituido)-1,2,4-triazinas e intermediario para realizar el procedimiento
DE3069556D1 (en) * 1979-08-16 1984-12-06 Wellcome Found Solid pharmaceutical formulation containing substitued phenyl-triazines
EP0093186B1 (de) * 1982-05-03 1986-07-09 Richardson Vicks Limited Pharmazeutisches Präparat zur topischen Behandlung von Akne
GB8328757D0 (en) * 1983-10-27 1983-11-30 Wellcome Found Chemical compounds

Also Published As

Publication number Publication date
KR910002254B1 (ko) 1991-04-08
DK275987A (da) 1987-12-01
DK275987D0 (da) 1987-05-29
IL82710A (en) 1992-01-15
GR3001942T3 (en) 1992-11-23
IE871415L (en) 1987-11-30
FI90770C (fi) 1994-03-25
AU7368487A (en) 1987-12-03
JPH0751571B2 (ja) 1995-06-05
FI90770B (fi) 1993-12-15
ES2021709B3 (es) 1991-11-16
NZ220497A (en) 1990-05-28
JPS62289570A (ja) 1987-12-16
FI872406A0 (fi) 1987-05-29
AU597982B2 (en) 1990-06-14
IE60626B1 (en) 1994-07-27
EP0247892A1 (de) 1987-12-02
FI872406L (fi) 1987-12-01
US4847249A (en) 1989-07-11
HU196769B (en) 1989-01-30
IL82710A0 (en) 1987-11-30
ZA873896B (en) 1989-01-25
DK166278C (da) 1993-08-23
KR870011112A (ko) 1987-12-21
EP0247892B1 (de) 1991-04-24
GB8613183D0 (en) 1986-07-02
CA1286670C (en) 1991-07-23
HUT45978A (en) 1988-09-28
DK166278B (da) 1993-03-29
DE3769516D1 (de) 1991-05-29

Similar Documents

Publication Publication Date Title
ATE62902T1 (de) Triazin-salze.
NO2006018I2 (no) Entekavir
MD950086A (ro) Utilizare a analogilor nucleozidici ai 1,3-oxatiolanei in tratamentul hepatitei B Use of 1,3-oxathiolan nucleoside analogues in the treatment of hepatitis B
FI911763A7 (fi) N5-metyyli-5,6,7,8-tetrahydrofoolihapon ammoniumsuolat
GR3020369T3 (en) Xanthine derivatives
DE69122646D1 (de) Konzentrierte wässrige Tensidlösung
MX9203125A (es) Compuestos con actividad similar a la insulina, antidiabeticos.
DE3688776D1 (de) Hydroxyoxaalkylmelamine, verfahren zu ihrer herstellung und deren verwendung.
LV10923A (lv) Penciklovira atvasinajumi hepatita-B infekciju arstesanai
GR3004303T3 (de)
PH20020A (en) New 5-methyl-6-phenyl-4,5-dihydro-1,2,4-triazine derivatives,their composition and use
GB2277265A (en) Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for the treatment of pain and oedema
ES2038686T3 (es) Procedimiento para la preparacion de nuevos derivados del pirrol.
IT1183615B (it) Processo per preparare derivati di 6-ammino-3idrazinopiridazina
IT8885584A0 (it) Sistema di bloccaggio dell'apertura contemporanea di piu' cassetti in una cassettiera.
FR2372816A1 (fr) Benzisothiazolones et medicaments contenant ces substances
ATE18410T1 (de) Kristallines human-leukocyten-interferon.
DE3363560D1 (en) Finely pulverized 2,4-diamino-6-(2,5-dichlorophenyl)-1,3,5-triazine and pharmaceutically acceptable acid addition salts thereof
IT8522214V0 (it) Bottone del tipo detto "automatico" avente anche una funzione di gancio per un bloccaggio stabile delle due parti del bottone.
SU1499898A1 (ru) СОЛИ 9-ДИАЛКИЛАМИНОЭТИЛ-2-МЕТИЛ-3-ТЕНОИЛИМИДАЗО[1,2-а]БЕНЗИМИДАЗОЛА, ОБЛАДАЮЩИЕ АНТИРАДИОМИМЕТИЧЕСКИМ ДЕЙСТВИЕМ
RO102375A2 (ro) Procedeu de alchilare a 2-cian-2-hidroxiiminoacetamidei (cianacetamidoximei)
NO885273D0 (no) 5,6-dihydro-2-(substituert fenyl)-1,2,4-triazin-3,5(2h,4h)-dioner.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee